問卷

TPIDB > Search Result

Search Result

篩選

List

2394Cases

2019-08-01 - 2022-07-31

Phase II

A noval tau tracer ([ 18F]PM-PBB3) in young onset dementia: clinical and neuroimaging study
  • Condition/Disease

    *PRESENILE DEMENTIA;SENILE DEMENTIA, UNCOMPLICATED;DEMENTIA IN CONDITIONS CLASSIFIED ELSEWHERE;AMNESTIC  SYNDROME

  • Test Drug

    (1)[F18] AV-45 (2) [F-18] PM-PBB3

Participate Sites
3Sites

Recruiting3Sites

2021-06-20 - 2023-10-11

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-04-01 - 2019-04-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting1Sites

2014-02-01 - 2016-01-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-01-01 - 2016-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2018-01-01 - 2019-12-31

Others

A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.
  • Condition/Disease

    Angina

  • Test Drug

    Ranolazine

Participate Sites
3Sites

Terminated3Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2012-05-15 - 2014-04-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2008-07-15 - 2011-07-14

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2014-03-01 - 2015-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2017-04-05 - 2018-09-27

Phase II/III

A TWO-PART PHASE 2/ 3 MULTICENTRE, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY OF VARLITINIB PLUS MFOLFOX6 VERSUS PLACEBO PLUS MFOLFOX6 IN SUBJECTS WITH HER1/ HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER WITHOUT PRIOR EXPOSURE TO SYSTEMIC THERAPY
  • Condition/Disease

    HER1/ HER2 CO-EXPRESSING ADVANCED OR METASTATIC GASTRIC CANCER

  • Test Drug

    Varlitinib

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites